These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16710914)

  • 1. Drug-related hepatotoxicity.
    McIntyre K
    N Engl J Med; 2006 May; 354(20):2191-3; author reply 2191-3. PubMed ID: 16710914
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hepatotoxicity in patients treated with endothelin receptor antagonists: systematic review and meta-analysis of randomized clinical trials].
    Macías Saint-Gerons D; de la Fuente Honrubia C; Montero Corominas D; Catalá-López F
    Med Clin (Barc); 2014 Apr; 142(8):333-42. PubMed ID: 23540381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver toxicity of sitaxentan in pulmonary arterial hypertension.
    Galiè N; Hoeper MM; Simon J; Gibbs R; Simonneau G;
    Eur Heart J; 2011 Feb; 32(4):386-7. PubMed ID: 21416695
    [No Abstract]   [Full Text] [Related]  

  • 4. Severe hepatotoxicity in a patient on bosentan upon addition of methotrexate: reversible with resumption of methotrexate without bosentan.
    Dwyer N; Jones G; Kilpatrick D
    J Clin Rheumatol; 2009 Mar; 15(2):88-9. PubMed ID: 19265355
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature.
    Eriksson C; Gustavsson A; Kronvall T; Tysk C
    J Gastrointestin Liver Dis; 2011 Mar; 20(1):77-80. PubMed ID: 21451802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bosentan for pulmonary hypertension.
    Dietrich CG; Geier A; Lammert F
    N Engl J Med; 2002 Jul; 347(4):292-4; author reply 292-4. PubMed ID: 12141332
    [No Abstract]   [Full Text] [Related]  

  • 7. CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers.
    Markert C; Burhenne J; Weiss J; Mikus G; Haefeli WE
    Clin Pharmacol Ther; 2014 Mar; 95(3):250-1. PubMed ID: 24048276
    [No Abstract]   [Full Text] [Related]  

  • 8. CYP2C9, SLCO1B1, SLCO1B3, and ABCB11 polymorphisms in patients with bosentan-induced liver toxicity.
    Roustit M; Fonrose X; Montani D; Girerd B; Stanke-Labesque F; Gonnet N; Humbert M; Cracowski JL
    Clin Pharmacol Ther; 2014 Jun; 95(6):583-5. PubMed ID: 24842639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to "CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers".
    Markova SM; Schwartz JB; Kroetz DL
    Clin Pharmacol Ther; 2014 Mar; 95(3):252. PubMed ID: 24346422
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of pulmonary arterial hypertension: endothelin-receptor antagonists].
    Hoeper MM
    Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S308-10. PubMed ID: 17139593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Achilles heel of endothelin receptor therapy for pulmonary arterial hypertension.
    Corris PA; Langleben D
    Eur Respir J; 2010 Feb; 35(2):460-1; author reply 461. PubMed ID: 20123858
    [No Abstract]   [Full Text] [Related]  

  • 12. Managing the risk of drug-induced liver injury.
    Watkins PB
    Clin Pharmacol Ther; 2013 Dec; 94(6):629-31. PubMed ID: 24241638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug eruption due to bosentan in a patient with systemic sclerosis.
    Nagai Y; Yamanaka M; Nishimura S; Nakano A; Hasegawa A; Ishikawa O
    Mod Rheumatol; 2006; 16(3):188-90. PubMed ID: 16767560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Endothelin receptor antagonists in the new European guidelines on pulmonary hypertension].
    Montani D; Humbert M
    Rev Mal Respir; 2010 Feb; 27(2):103-5. PubMed ID: 20206056
    [No Abstract]   [Full Text] [Related]  

  • 15. [Bosentan: a considerable increase in the survival of patients with pulmonary hypertension associated with systemic rheumatic diseases].
    Volkov AV; Iudkina NN; Nikolaeva EV; Kurmukov IA; Glukhova SI; Nasonov EL
    Ter Arkh; 2014; 86(5):32-9. PubMed ID: 25026800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan.
    Don GW; Joseph F; Celermajer DS; Corte TJ
    Intern Med J; 2012 Dec; 42(12):1351-4. PubMed ID: 23253000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hidden hazards of Bosentan therapy in pulmonary hypertension.
    Sethi S; Sethi R; Wareham C
    Ann Card Anaesth; 2008; 11(2):138; author reply 138-9. PubMed ID: 18603762
    [No Abstract]   [Full Text] [Related]  

  • 18. Liver impairment after concomitant administration of bosentan and clarithromycin in systemic sclerosis.
    Caramaschi P; Mahamid H; Bambara LM; Biasi D
    Joint Bone Spine; 2010 Jan; 77(1):81-2. PubMed ID: 20022782
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term hepatic safety of ambrisentan in patients with pulmonary arterial hypertension.
    Ben-Yehuda O; Pizzuti D; Brown A; Littman M; Gillies H; Henig N; Peschel T
    J Am Coll Cardiol; 2012 Jul; 60(1):80-1. PubMed ID: 22578922
    [No Abstract]   [Full Text] [Related]  

  • 20. Genetic susceptibility to hepatoxicity due to bosentan treatment in pulmonary hypertension.
    Seyfarth HJ; Favreau N; Tennert C; Ruffert C; Halank M; Wirtz H; Mössner J; Rosendahl J; Kovacs P; Wittenburg H
    Ann Hepatol; 2014; 13(6):803-9. PubMed ID: 25332267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.